NLE Immune System & Immunologic Disorders — Autoimmune Disorders and HIV/AIDSStudy Notes

Autoimmune disorders arise when the immune system loses self-tolerance, the normal capacity to distinguish between self-antigens (the body's own proteins and tissues) and non-self-antigens (foreign pathogens). In autoimmunity, the immune system produces autoantibodies (antibodies that bind to the body's own antigens) or self-reactive T cells that attack the body's own tissues, initiating chronic inflammation and progressive tissue destruction. The result is a spectrum of systemic and organ-specific diseases.

Key Pathophysiologic Mechanisms:

• Loss of Central Tolerance: Autoreactive T and B cells that should have been eliminated in the thymus and bone marrow escape into circulation.
• Loss of Peripheral Tolerance: Regulatory T cells (Tregs) and other suppressive mechanisms fail to control autoreactive cells in peripheral tissues.
• Genetic Predisposition: Strong associations with HLA (human leukocyte antigen) genes; twin concordance rates often exceed 50%, indicating hereditary risk.
• Environmental Triggers: Infections, ultraviolet exposure, smoking, and physical/emotional stress can precipitate autoimmune disease in genetically susceptible individuals.
• Immune-Complex Deposition: Type III hypersensitivity reactions occur when autoantibodies form immune complexes that deposit in tissues (e.g., kidneys, joints, skin) and activate complement, causing inflammation.
• Direct Cellular Cytotoxicity: Type II and Type IV hypersensitivity reactions also contribute; autoantibodies bind to cell-surface antigens (Type II) or self-reactive T cells directly attack target cells (Type IV).

Epidemiologic Patterns:

• More common in women of childbearing age (female-to-male ratio often 9:1).
• Tend to follow a relapsing-remitting course with unpredictable flares (periods of active disease) and remissions (periods of clinical quiescence).
• Higher prevalence in certain populations (e.g., SLE more common in Asian, African-American, and Hispanic populations).
• Often cluster within families, suggesting genetic factors.

Nursing Considerations for Autoimmune Disorders:
Autoimmune patients require holistic, long-term management emphasizing disease education, trigger identification, medication adherence, lifestyle modifications, and psychological support. Many patients experience significant anxiety and depression due to the chronic, unpredictable nature of their illness, functional limitations, and medication side effects. Nurses must be sensitive to these psychosocial dimensions while maintaining focus on physiologic management and preventing complications.

Systemic Lupus Erythematosus (SLE) is the archetypal systemic autoimmune disease and a high-yield NLE topic. It is a chronic, multisystem disorder characterized by production of multiple autoantibodies and deposition of immune complexes in tissues throughout the body. SLE can affect virtually every organ system, making it unpredictable and requiring vigilant, multidisciplinary management.

Pathophysiology:
SLE is fundamentally a Type III hypersensitivity disease. Autoantibodies, particularly against double-stranded DNA (dsDNA) and nucleosomal antigens, form immune complexes that circulate in the blood and deposit in tissues. These complexes activate the complement cascade, causing inflammation, complement depletion, tissue damage, and a self-perpetuating cycle of autoimmunity. Defective clearance of apoptotic cell debris may also contribute by providing a continuous source of nuclear antigens.

Multisystem Manifestations:

1. Cutaneous (Skin) Manifestations — Most Recognizable

• Malar ("Butterfly") Rash: The classic finding—erythema across the cheeks and bridge of nose, sparing the nasolabial folds (the area between the nose and upper lip). This rash is fixed or worsens with sun exposure and is one of the most distinctive signs of SLE.
• Discoid Rash: Scarring, coin-shaped lesions, usually on the face, scalp, and upper trunk.
• Photosensitivity: Exaggerated skin reaction to ultraviolet (UV) light; patients develop rashes or systemic flares triggered by sun exposure. This is so characteristic that sun avoidance and photoprotection are central to SLE management.
• Oral Ulcers: Painless or mildly painful ulcers on the hard palate, buccal mucosa, or gums.
• Alopecia (Hair Loss): Often patchy and reversible with disease control.

2. Musculoskeletal Manifestations

• Arthralgia and Arthritis: Non-erosive (joints are not permanently damaged, unlike RA), usually affecting small joints of the hands, wrists, and knees. Pain and swelling typically are symmetric and worse in the morning.
• Myalgia: Muscle pain, sometimes severe.

3. Renal Manifestations (Lupus Nephritis) — The Most Serious Complication

• Affects up to 50% of SLE patients and is a leading cause of morbidity and mortality.
• Pathophysiology: Immune-complex deposition in glomeruli causes inflammation, proliferation, and glomerulonephritis.
• Clinical features: Proteinuria (often nephrotic-range, >3.5 g/day), hematuria, rising serum creatinine, reduced GFR, hypertension, and edema.
• WHO Classification ranges from Class I (minimal changes) to Class VI (advanced sclerosis); higher classes indicate more severe disease and higher risk of progression to end-stage renal disease (ESRD).
• Nursing priorities: strict BP control (goal <130/80 mmHg), monitoring for proteinuria and rising creatinine, adherence to immunosuppression, dietary sodium/fluid restriction if needed, and early nephrology referral.

4. Hematologic Manifestations

• Anemia: Usually mild-to-moderate, often hemolytic (autoantibodies against RBCs).
• Leukopenia: WBC <4,500/mm³, predisposes to infection.
• Thrombocytopenia: Low platelets; severe thrombocytopenia requires close monitoring and may necessitate corticosteroids or other interventions.

5. Cardiopulmonary Manifestations

• Pericarditis: Inflammation of the pericardial sac, causing chest pain (worse with breathing and lying flat), pericardial effusion, and potentially tamponade.
• Pleuritis: Inflammation of pleural membranes; causes pleuritic chest pain (worse with breathing/coughing).
• Lupus Myocarditis: Less common but serious; causes myocardial dysfunction.
• Pulmonary Hemorrhage: Rare but life-threatening; presents with hemoptysis and respiratory distress.
• Accelerated Atherosclerosis: SLE patients, especially those on long-term corticosteroids, have increased cardiovascular risk.

6. Neuropsychiatric Manifestations (CNS Lupus)

• Seizures: Can occur without other warning signs; require anti-epileptic drugs and immunosuppression.
• Cognitive Dysfunction: Memory problems, difficulty concentrating, "lupus fog."
• Psychosis: Mood swings, depression, severe psychiatric symptoms; can be lupus-related or medication-related (steroids can cause mood disturbance).
• Cerebrovascular Events: Increased stroke risk due to antiphospholipid antibodies (which can coexist with SLE).
• Peripheral Neuropathy: Sensory or motor deficits.

7. Constitutional Symptoms

• Persistent fatigue (often the most disabling symptom for patients).
• Fever.
• Weight loss.
• Malaise.

Other Manifestations:

• Raynaud Phenomenon: Episodic color changes (white→blue→red) of fingers and toes in response to cold or stress; due to vasospasm.
• Lymphadenopathy: Generalized swelling of lymph nodes.
• Splenomegaly: Enlarged spleen.

SLE Flare Triggers — Critical for Patient Education:
A fundamental nursing role is to educate patients about avoiding triggers that precipitate flares:

1. Sun/Ultraviolet (UV) Exposure: The most important and modifiable trigger; UV light directly activates B cells and triggers inflammatory responses.
2. Infection: Bacterial, viral, or fungal infections can precipitate flares; patients should promptly seek treatment for any infection.
3. Physical and Emotional Stress: Major life stressors, work stress, relationship problems, or psychological trauma can trigger disease activity.
4. Fatigue and Inadequate Rest: Insufficient sleep and overexertion worsen disease; balance is essential.
5. Pregnancy: Pregnancy is a unique risk; hormonal changes can precipitate flares. Patients require close obstetric-rheumatologic co-management.
6. Certain Medications: Drugs like procainamide, hydralazine, and isoniazid can induce lupus-like syndromes (drug-induced lupus); some medications may exacerbate existing SLE.
7. Abrupt Discontinuation of Corticosteroids: Rapid steroid tapers can precipitate severe flares; tapering must be gradual and supervised.

Diagnostic Criteria and Laboratory Findings:

SLE diagnosis requires meeting 4 of 11 criteria from the 2019 EULAR/ACR criteria, including clinical and immunologic findings. Key laboratory tests include:

• ANA (Antinuclear Antibody): Positive in >95% of SLE patients (sensitive but not specific; positive ANA alone does not diagnose SLE). Typically high titers (1:320 or higher).
• Anti-Double-Stranded DNA (Anti-dsDNA): Highly specific for SLE (~70% positive); correlates with lupus nephritis and disease activity. Titers rise and fall with disease flares.
• Anti-Smith (Anti-Sm) Antibodies: Highly specific for SLE (~30% positive); less correlated with activity but when present, is pathognomonic.
• Complement Levels (C3, C4): Decrease during active disease as complement is consumed by immune complexes; rising levels suggest remission.
• CBC: Documents anemia, leukopenia, thrombocytopenia.
• Comprehensive Metabolic Panel: Assess renal function (creatinine, BUN), electrolytes.
• Urinalysis: Proteinuria, RBC casts, WBC casts indicate glomerulonephritis.
• ESR (Erythrocyte Sedimentation Rate): Elevated in active disease; nonspecific.
• CRP (C-Reactive Protein): Less sensitive than ESR in SLE; CRP elevation may suggest concurrent infection or other inflammation.
• Coagulation Studies: Screen for antiphospholipid antibodies if history of thrombosis or recurrent pregnancy loss.

Pharmacologic Management:

1. NSAIDs (Non-Steroidal Anti-Inflammatory Drugs)

• Used for mild disease, arthralgia, and arthritis.
• Examples: Naproxen, indomethacin, ibuprofen.
• Nursing considerations: Monitor for GI upset/ulceration (use PPI if needed), renal function (NSAIDs can worsen renal disease in SLE), and cardiovascular effects. NSAIDs may also increase photosensitivity.

2. Antimalarials — Hydroxychloroquine (Plaquenil) — A Cornerstone

• Central to SLE management; used for mild-to-moderate disease, skin and joint manifestations, and to reduce flare frequency.
• Mechanism: Immunomodulatory; reduces antigen presentation and autoantibody production.
• Dosing: Typically 200-400 mg/day.
• Critical nursing consideration: Retinal Toxicity Risk. Hydroxychloroquine deposits in the retina and can cause irreversible vision loss (retinopathy) with prolonged use, especially at high cumulative doses. Baseline ophthalmology examination is mandatory before starting, and periodic eye exams (at least annually) are required during therapy. Patients must be counseled about vision changes and the importance of ophthalmology monitoring.
• Benefits extend beyond SLE management: reduces risk of flares, reduces cardiovascular events, and improves outcomes in lupus nephritis.

3. Corticosteroids (Prednisone, Methylprednisolone)

• Used for moderate-to-severe flares and organ-threatening disease (nephritis, CNS lupus, pericarditis, pulmonary hemorrhage).
• Powerful anti-inflammatory and immunosuppressive effects.

• Nursing considerations:

  • Never stop abruptly; adrenal suppression can occur, and rapid withdrawal can precipitate acute flare or adrenal crisis.
  • Monitor for infection; corticosteroids mask fever and other signs of infection; teach patients to report any symptoms promptly.
  • Hyperglycemia: Steroids raise blood glucose; patients on chronic steroids require glucose monitoring and may develop steroid-induced diabetes. Dietary counseling on low-glycemic foods is important.
  • Osteoporosis: Long-term steroid use causes bone loss. All patients on chronic steroids require calcium (1,200 mg/day), vitamin D (800-1,000 IU/day), and may need bisphosphonates (alendronate). Weight-bearing exercise is encouraged.
  • Hypertension: Steroids increase BP; close monitoring and antihypertensive management are needed.
  • Mood changes: Steroids can cause euphoria, irritability, depression, or insomnia; patients should report significant mood changes.
  • GI upset: Give with food; monitor for ulceration.
  • Tapering should be gradual (typically 5-10% reduction every 1-2 weeks once disease is controlled).

4. Immunosuppressants (for Severe Organ Disease, especially Lupus Nephritis)

• Azathioprine (Imuran): A purine analog; used as steroid-sparing agent and for lupus nephritis. Dose typically 1-2 mg/kg/day. Nursing considerations: monitor CBC for bone marrow suppression (leukopenia, thrombocytopenia, anemia), liver function, and nausea (take with food); risk of infection.
• Mycophenolate Mofetil (MMF, Cellcept): Selectively inhibits lymphocyte proliferation; increasingly preferred for lupus nephritis, often combined with corticosteroids. Dose typically 1,000-3,000 mg/day in divided doses. Nursing considerations: significant GI side effects (nausea, diarrhea, abdominal pain) are common; monitor CBC and renal function; teratogenic (Category D—avoid in pregnancy).
• Cyclophosphamide (Cytoxan): Reserved for severe, life-threatening lupus (severe nephritis, CNS lupus, pulmonary hemorrhage). Potent alkylating agent; given as IV pulses typically monthly for 6 months. Nursing considerations: severe bone marrow suppression (requires close CBC monitoring), hemorrhagic cystitis (encourage high fluid intake and frequent voiding), severe infection risk, nausea/vomiting, alopecia, premature ovarian failure (significant concern for women of childbearing age), and potential infertility. Requires close monitoring in specialized centers.

5. Biologic Therapies

• Belimumab (Benlysta): A monoclonal antibody against B-lymphocyte stimulator (BLyS), approved for active SLE. Administered IV or SC; reduces B-cell and autoantibody production. Nursing considerations: infusion reactions, infections, potential live-vaccine contraindication.
• Other biologics are under investigation for SLE.

Nursing Diagnoses and Interventions for SLE (NANDA-I Aligned):

Based on the comprehensive manifestations of SLE, typical nursing diagnoses include:

1. Acute Pain (related to arthritis, serositis) r/t inflammatory process

   • Interventions: NSAIDs, rest, ice/heat as appropriate, gentle ROM exercises, pain assessment.

2. Fatigue (related to chronic inflammation, anemia, metabolic effects) r/t inflammatory disease process

   • Interventions: Energy conservation education, rest/activity balance, nutritional support, assessment for depression.

3. Risk for Infection r/t immunosuppressive medications

   • Interventions: Hand hygiene education, monitoring for fever/signs of infection, avoiding exposure to known infections, pneumococcal and influenza vaccines (avoid live vaccines).

4. Impaired Skin Integrity r/t photosensitivity and rash

   • Interventions: Sun protection education (sunscreen SPF 30+, protective clothing, hats, shade), assessment of skin lesions.

5. Disturbed Body Image r/t alopecia, rash, steroid side effects (moon facies, weight gain, hirsutism)

   • Interventions: Therapeutic communication, cosmetic counseling, support groups, addressing underlying depression/anxiety.

6. Risk for Decreased Cardiac Tissue Perfusion r/t pericarditis/myocarditis

   • Interventions: Chest pain assessment, ECG monitoring, echocardiography, NSAIDs or steroids as ordered.

7. Risk for Impaired Renal Function r/t lupus nephritis

   • Interventions: Strict urinalysis and renal function monitoring, BP control, medication adherence, dietary sodium/protein restriction if needed, nephrology referrals.

8. Ineffective Coping r/t chronic, unpredictable disease

   • Interventions: Psychological assessment, mental health referrals, support groups, patient education, stress-reduction techniques.

Patient Education for SLE — Critical Nursing Role:

1. Sun Protection (Highest Priority):

   • Use broad-spectrum sunscreen SPF 30+ daily, even on cloudy days.
   • Wear protective clothing (long sleeves, pants), wide-brimmed hats.
   • Avoid peak sun hours (10 AM-4 PM).
   • Use lip balm with SPF.
   • UV-protective swimwear for beach/pool activities.

2. Medication Adherence:

   • Hydroxychloroquine and other drugs must be taken consistently to prevent flares.
   • Do not stop medications abruptly, especially corticosteroids.
   • Report side effects promptly.
   • Keep appointments for monitoring (bloodwork, eye exams).

3. Stress Management:

   • Teach relaxation techniques (deep breathing, meditation, progressive muscle relaxation).
   • Encourage participation in support groups (both in-person and online).
   • Discuss work accommodations if needed.
   • Screen for and address depression and anxiety.

4. Infection Prevention:

   • Report fever or signs of infection immediately.
   • Keep up with appropriate vaccinations (pneumococcal, influenza, but avoid live vaccines).
   • Avoid people with known infections.
   • Practice good hand hygiene.

5. Activity and Rest:

   • Encourage regular, moderate exercise (walking, swimming, yoga) as tolerated.
   • Prioritize adequate sleep (7-9 hours nightly).
   • Take rest breaks throughout the day.
   • Modify activities during flares.

6. Pregnancy Planning:

   • Counsel women of childbearing age about the risks of pregnancy in SLE (flare risk, renal complications, preeclampsia, fetal loss).
   • Discuss need for close obstetric-rheumatologic co-management.
   • Some medications are contraindicated in pregnancy (cyclophosphamide, mycophenolate); switching to safer alternatives before conception is needed.
   • Goal: optimize disease control pre-pregnancy to minimize flare risk during pregnancy.

7. Dietary Support:

   • Encourage anti-inflammatory diet (Mediterranean-style).
   • If on corticosteroids: sodium restriction, adequate calcium/vitamin D.
   • If on NSAIDs: take with food.
   • If on mycophenolate: take with food to reduce GI upset.

8. Monitoring and Adherence:

   • Teach signs/symptoms of flare (fever, rash worsening, joint pain, photosensitivity reaction).
   • Emphasize importance of regular lab monitoring (ANA, anti-dsDNA, complement, CBC, urinalysis, creatinine).
   • Stress importance of eye exams while on hydroxychloroquine.

Systemic sclerosis (scleroderma) is a chronic autoimmune connective-tissue disease characterized by pathologic fibrosis (excessive collagen deposition) of the skin and internal organs, combined with vascular injury (endothelial damage and vasospasm). The disease results in thickened, hardened skin and progressive organ dysfunction. Unlike SLE, scleroderma is driven more by fibrotic and vascular mechanisms than by immune complexes, though autoimmunity plays a role.

Pathophysiology:

• Excessive Collagen Synthesis: Activated fibroblasts produce abnormally large amounts of collagen I and III, exceeding normal tissue remodeling.
• Vascular Injury: Endothelial damage leads to vasospasm, reduced capillary density, and ischemia.
• Immune Activation: T cell infiltration and production of pro-fibrotic cytokines (TGF-β, CTGF) drive fibroblast activation and collagen production.
• Genetic and Environmental Factors: Rare, familial cases suggest genetic contribution; possible environmental triggers (silica, organic solvents) have been hypothesized.

Two Major Forms:

1. Limited Cutaneous Systemic Sclerosis (Limited Scleroderma or CREST Syndrome) — ~70% of patients

• Skin thickening limited to hands, forearms, face, and neck; does not extend proximal to the elbows or knees.

• Associated with CREST syndrome: a useful mnemonic for the clinical features:

  • C: Calcinosis — calcium deposits in subcutaneous tissues, especially fingertips; can be painful and lead to ulceration.
  • R: Raynaud's Phenomenon — episodic attacks of vasospasm causing color changes (white→blue→red) of fingers/toes in response to cold or emotional stress; often the earliest manifestation. Painful and bothersome for patients.
  • E: Esophageal Dysmotility — dysfunction of esophageal motility, causing dysphagia and GERD.
  • S: Scleroderma (skin tightening).
  • T: Telangiectasia — dilated capillaries, visible as red spots on face and hands.
• Associated with anticentromere antibodies (ACA) and anti-CREST antibodies.
• Generally better prognosis than diffuse form; slower progression; lower mortality (primarily due to pulmonary hypertension and renal disease).

2. Diffuse Cutaneous Systemic Sclerosis (Diffuse Scleroderma) — ~30% of patients

• Skin thickening extends to trunk, upper arms, and thighs; more severe, rapid onset.
• Associated with anti-topoisomerase I (anti-Scl-70) antibodies.
• Higher risk of early, severe internal-organ disease (interstitial lung disease, scleroderma renal crisis, cardiac involvement).
• Worse prognosis; higher mortality from organ involvement.

Multisystem Clinical Manifestations:

1. Cutaneous (Skin) — The Hallmark

• Progressive Skin Thickening: Begins distally (fingers/hands) and, in diffuse disease, extends proximally. Skin becomes thick, shiny, taut, and loses normal elasticity.
• Tight, Mask-Like Face: Limited facial expression, microstomia (small mouth opening due to skin tightening around lips), tight chin.
• Sclerodactyly: Fingers become stiff and tapered; range of motion is progressively limited, affecting function (difficulty with fine motor tasks, gripping, writing).
• Skin Ulcers: Often on fingertips or over bony prominences; slow to heal due to ischemia from vasculopathy.
• Alopecia and Loss of Hair Follicles: Skin loses hair, sweat glands, and other appendages.

2. Vascular — Raynaud Phenomenon (Often the Earliest Sign)

• Pathophysiology: Vasospasm of small arteries and arterioles, combined with reduced capillary density, leads to periodic ischemia.
• Clinical Presentation: Episodic color changes—typically white (pallor from vasospasm) → blue/purple (cyanosis from deoxygenation) → red (reactive hyperemia on rewarming). Episodes last minutes to hours.
• Triggers: Cold exposure, emotional stress, smoking.
• Symptoms: Numbness, tingling, pain during attacks. Severe Raynaud can lead to digital ulcers and gangrene if ischemia is severe.
• Nursing considerations: Teach patients to avoid cold, wear warm gloves/socks, avoid smoking, manage stress, and report digital ulcers or color changes that don't resolve.

3. Gastrointestinal — Scleroderma Affects the GI Tract Extensively

• Esophageal Dysmotility: Loss of normal peristalsis, especially in the lower two-thirds, causes severe dysphagia (difficulty swallowing both solids and liquids, sometimes painful). This is very common and troubling for patients.
• GERD (Gastroesophageal Reflux Disease): Incompetent lower esophageal sphincter combined with reduced esophageal clearance leads to chronic reflux, heartburn, regurgitation. Risk of reflux esophagitis and Barrett metaplasia.
• Gastric Dysmotility: Delayed gastric emptying causes early satiety and abdominal bloating; nausea and anorexia.
• Small-Bowel and Colonic Dysmotility: Malabsorption, diarrhea, constipation, and bacterial overgrowth syndrome (due to dilated loops and reduced motility).
• Nursing management: Small frequent meals, remain upright for 2-3 hours after eating, elevate head of bed, use proton pump inhibitors (PPIs) or H2 blockers for reflux, encourage adequate hydration and nutrition, monitor for signs of malabsorption (weight loss, vitamin deficiencies).

4. Pulmonary (Lungs) — The Leading Cause of Death

• Interstitial Lung Disease (ILD): Progressive pulmonary fibrosis affecting up to 80% of scleroderma patients. Collagen deposition in lung parenchyma and pleura causes stiffness, reduced compliance, and impaired gas exchange.

  • Presents with progressive dyspnea on exertion, nonproductive cough.
  • PFTs show reduced FVC, reduced DLCO.
  • High-resolution CT (HRCT) shows reticular opacities, ground-glass, and traction bronchiectasis.
  • Progressive ILD can lead to respiratory failure.

• Pulmonary Hypertension (PH): Elevation of pulmonary vascular pressure due to precapillary (intrinsic vascular disease) or postcapillary (from left-heart disease or ILD) mechanisms. PH is the leading cause of death in scleroderma.

  • Presents with dyspnea, right-heart strain, peripheral edema, syncope.
  • Diagnosed by right-heart catheterization; echocardiography estimates systolic pulmonary pressure.
  • Treatment is complex; vasodilators (phosphodiesterase-5 inhibitors, endothelin-receptor antagonists) may help.
• Nursing priorities: Monitor for dyspnea, cough, exercise tolerance; pulse oximetry; encourage PFTs and echocardiography screening; support smoking cessation; counseling on activity limitations; early recognition of signs of right-heart failure.

5. Renal — Scleroderma Renal Crisis

• Rare but Life-Threatening: Occurs in ~5-10% of scleroderma patients, usually diffuse disease.
• Pathophysiology: Acute arterial occlusion due to intimal proliferation (no immune-complex deposition as in SLE). Leads to acute renal ischemia, renin release, severe hypertension, and rapid progression to acute kidney injury.
• Clinical Presentation: Sudden-onset severe hypertension (often >180/120 mmHg), rising creatinine (rapidly increasing), oliguria, signs of microangiopathic hemolytic anemia (MAHA) with schistocytes on blood smear.
• Risk Factors: Diffuse scleroderma, high-dose corticosteroids (controversial; thought to increase risk by reducing renal perfusion), rapid skin progression.
• Management: ACE inhibitors are first-line and potentially lifesaving — they reduce renin release and halt progression. Strict BP control is essential. Dialysis may be needed temporarily; many patients recover renal function with ACE inhibitor therapy, though some progress to ESRD.
• Nursing priorities: Monitor BP closely (daily or more often), watch for rising creatinine, educate about signs of renal crisis (rapid BP rise, oliguria, fatigue), ensure medication adherence to ACE inhibitors, monitor for MAHA signs.

6. Cardiac — Myocardial Involvement

• Scleroderma Myocarditis: Patchy fibrosis and inflammation of the myocardium; can cause conduction abnormalities, arrhythmias, and heart failure.
• Pericarditis: Less common than myocarditis; can cause pericardial effusion.
• Nursing considerations: ECG monitoring, assessment for dyspnea and edema, echocardiography if indicated.

7. Musculoskeletal — Limited Compared to SLE

• Unlike SLE, polyarthritis is less common, and arthritis is nonerosive.
• Muscle weakness and myositis can occur but are less frequent.

Laboratory and Diagnostic Findings:

• Autoantibodies:

  • Anti-centromere antibodies (ACA): Associated with limited disease; ~50-80% of limited-disease patients.
  • Anti-topoisomerase I (Anti-Scl-70): Associated with diffuse disease; ~30% of patients. Correlates with ILD risk.
  • Anti-RNA polymerase III: Associated with diffuse disease and scleroderma renal crisis; poor prognosis.
  • Anti-Th/To, anti-Ku: Less common but associated with specific manifestations.
• CBC, CMP: Screen for anemia (may be present from MAHA in renal crisis or chronic disease), electrolyte abnormalities, renal function.
• Urinalysis: Proteinuria and hematuria in renal crisis; monitor baseline.
• High-Resolution CT Chest: Assesses extent of interstitial lung disease; gold standard for diagnosis.
• Pulmonary Function Tests (PFTs): FVC, DLCO, TLC; monitor progression of ILD.
• Echocardiography: Estimates pulmonary artery pressure; assesses left-ventricular function.
• Skin Biopsy: Confirms diagnosis (shows dermal fibrosis, loss of subcutaneous fat, thinning epidermis); rarely needed if clinical and serologic findings are clear.

Pharmacologic and Supportive Management:

1. For Raynaud Phenomenon:

• Non-pharmacologic (First-Line):

  • Keep hands warm — wear gloves, mittens in cold weather.
  • Avoid cold-water exposure; use warm water for washing.
  • Avoid smoking and secondhand smoke (nicotine causes vasoconstriction).
  • Manage stress — tension triggers episodes.
  • Use hand warmers, electric blankets.
  • Avoid vasoconstrictive drugs (decongestants with pseudoephedrine, caffeine in excess).

• Pharmacologic (If Severe):

  • Calcium-Channel Blockers: Nifedipine (extended-release, 30-90 mg daily) or amlodipine are first-line; relax vascular smooth muscle, reduce vasospasm frequency and severity.
  • Alpha-Blockers: Prazosin can help severe Raynaud.
  • Topical Nitrates: Nitroglycerin ointment on affected fingers; helps by vasodilation.
  • Phosphodiesterase-5 Inhibitors: Sildenafil may help severe Raynaud, especially if pulmonary hypertension is present.

2. For GI Manifestations:

• Reflux: PPIs (omeprazole, pantoprazole) or H2-blockers; prokinetic agents (metoclopramide) to enhance gastric emptying.
• Dysphagia: Small, frequent, soft meals; remain upright after eating; elevate head of bed; swallowing evaluation if severe.
• Malabsorption: Supplemental vitamins (especially fat-soluble vitamins A, D, E, K if steatorrhea present); nutritional support.
• Bacterial Overgrowth: Rotating antibiotics (metronidazole, ciprofloxacin) if indicated.

3. For Pulmonary Fibrosis:

• Limited evidence-based pharmacotherapy.
• Immunosuppression: Some evidence for mycophenolate or cyclophosphamide in early ILD; benefit remains unclear and not standard of care.
• Supportive Care: Supplemental oxygen if hypoxemic; pulmonary rehabilitation; monitor with PFTs and HRCT.
• ACE Inhibitors or ARBs: Protect kidneys and may have anti-fibrotic properties.

4. For Pulmonary Hypertension:

• Phosphodiesterase-5 Inhibitors: Sildenafil (Revatio) — increases nitric oxide, causes pulmonary vasodilation.
• Endothelin-Receptor Antagonists: Bosentan, ambrisentan — block endothelin, a vasoconstrictor and pro-fibrotic mediator.
• Prostaglandins: Epoprostenol, inhaled iloprost — vasodilators; for severe PH.
• Supportive: diuretics for fluid overload, anticoagulation if thrombosis risk, oxygen as needed.

5. For Scleroderma Renal Crisis:

• ACE Inhibitors: First-line; lisinopril, enalapril, ramipril. Must be started urgently upon diagnosis; can halt progression and allow recovery of renal function in many patients. Do not delay for "borderline" elevations in creatinine.
• Aggressive BP Control: Goal <140/90 mmHg; may need multiple agents.
• Dialysis: If AKI severe; many recover renal function with ACE inhibitors.
• Monitoring: Close renal function and BP monitoring; may need frequent visits initially.

6. General Skin Care and Hand Function:

• Emollients: Regular use of moisturizing creams to soften skin; helps with comfort and function.
• Range-of-Motion Exercises: Gentle, daily hand and finger exercises to preserve joint mobility and function. Occupational therapy is helpful.
• Compression Gloves: May help with swelling and stiffness.

Nursing Diagnoses for Scleroderma:

1. Impaired Physical Mobility r/t skin tightness and joint stiffness

   • Interventions: ROM exercises, occupational therapy, adaptive equipment.

2. Impaired Swallowing r/t esophageal dysmotility

   • Interventions: Small frequent meals, soft diet, remain upright, elevation of head of bed, swallow evaluation.

3. Chronic Pain r/t Raynaud attacks, digital ulcers, myalgia

   • Interventions: Teach warmth measures, calcium-channel blockers, pain assessment, analgesics as needed.

4. Ineffective Tissue Perfusion (Peripheral) r/t vasospasm and vascular disease

   • Interventions: Warmth measures, smoking cessation, stress management, monitor for digital ulcers.

5. Risk for Impaired Skin Integrity r/t thickened, taut skin and ischemia

   • Interventions: Skin care with emollients, monitoring for ulcers, protective measures.

6. Risk for Compromised Respiratory Function r/t pulmonary fibrosis and hypertension

   • Interventions: Monitor dyspnea, oxygen saturation, PFTs, echocardiography; supplemental oxygen; activity counseling.

7. Risk for Acute Kidney Injury r/t scleroderma renal crisis

   • Interventions: Strict BP and renal function monitoring, ACE inhibitor adherence, prompt treatment of hypertension.

Patient Education for Scleroderma:

1. Raynaud Phenomenon Management:

   • Keep hands warm at all times; wear gloves even in air conditioning.
   • Avoid smoking (nicotine causes vasoconstriction).
   • Avoid cold-water exposure; use warm water.
   • Manage stress; practice relaxation techniques.
   • Avoid vasoconstrictive medications and excess caffeine.

2. GI Symptom Management:

   • Eat small, frequent meals (5-6 per day rather than 3 large meals).
   • Eat soft, moist foods; avoid hard, dry, spicy foods.
   • Remain upright for 2-3 hours after eating.
   • Elevate head of bed 30-45 degrees.
   • Sip water frequently throughout the day.
   • Report signs of malabsorption (weight loss, pale stools) promptly.

3. Medication Adherence:

   • Especially important for ACE inhibitors (for renal protection and renal crisis prevention), calcium-channel blockers for Raynaud, PPIs for reflux.
   • Understand that these medications prevent disease progression and complications.

4. Hand and Skin Care:

   • Use moisturizing creams regularly; emollients are essential.
   • Perform gentle ROM exercises daily to maintain function.
   • Avoid harsh soaps; use gentle, fragrance-free cleansers.
   • Inspect skin regularly for ulcers, especially on fingertips; report immediately.

5. Respiratory Health:

   • Report new or worsening dyspnea, persistent cough to provider immediately.
   • Don't ignore breathing problems; early evaluation is crucial.
   • Use supplemental oxygen if prescribed; understand that it reduces strain on the heart.
   • Consider pulmonary rehabilitation if ILD is present.

6. Kidney Health:

   • Understand the risk of scleroderma renal crisis, especially if diffuse disease.
   • Monitor BP at home; report sudden increases.
   • Check BP regularly; attend appointments for renal function testing.
   • Take ACE inhibitors exactly as prescribed — they protect the kidneys.
   • Report oliguria, dark urine, unusual fatigue immediately.

Sjögren's syndrome is an autoimmune disorder in which lymphocytes (primarily T and B cells) infiltrate and progressively destroy the exocrine (moisture-producing) glands, particularly the lacrimal glands (tears) and salivary glands (saliva). The result is a chronic condition characterized by severe dry eyes and dry mouth. Sjögren's can occur alone (primary Sjögren's) or alongside other autoimmune diseases like SLE or rheumatoid arthritis (secondary Sjögren's).

Pathophysiology:

• Lymphocytic Infiltration: T and B cells accumulate in lacrimal and salivary glands, causing chronic inflammation.
• Glandular Destruction: Progressive destruction of acinar cells (the secretory cells) leads to loss of gland function.
• Autoantibody Production: Primarily against muscarinic-3 (M3) receptors and other intracellular antigens, leading to further gland dysfunction.
• Genetic and Environmental Factors: HLA associations (HLA-B8, HLA-DR3, HLA-DQ2); female predominance suggests hormonal influences; possible viral triggers (EBV, CMV).

The Classic Triad:

1. Keratoconjunctivitis Sicca (Dry Eyes)

• Severely reduced tear production.
• Presents with eye dryness, irritation, gritty sensation (as if sand in the eyes), photophobia, and paradoxically, excessive tearing (reflex tearing in response to irritation).
• Risk of corneal scarring and vision loss if untreated.
• Schirmer test: Wetting <5 mm of paper strip in 5 minutes confirms reduced tear production.
• Rose Bengal or Lissamine Green Test: Dye uptake indicates damaged epithelium.
• Ocular staining score: Quantifies corneal and conjunctival damage.

2. Xerostomia (Dry Mouth)

• Severe reduction in salivary flow.
• Presents with difficulty swallowing (dysphagia), difficulty eating dry foods, oral discomfort, altered taste, difficulty wearing dentures.
• Major consequence: Increased caries risk — saliva normally buffers oral acids and has antimicrobial properties. Loss of saliva leads to rapid, severe dental decay affecting all teeth, especially at the gum line (cervical caries).
• Other oral complications: oral candidiasis (thrush), angular cheilitis (cracks at corners of mouth), difficulty with speech.

3. Arthritis/Arthralgias

• Polyarthralgia and nonerosive polyarthritis, often affecting small joints (hands, wrists, knees).
• Usually mild, unlike RA, but can contribute to functional impairment.

Extraglandular Manifestations (Occur in ~50% of Patients):

• Pulmonary: Interstitial lung disease, bronchitis.
• Renal: Interstitial nephritis, glomerulonephritis.
• GI: Esophageal dysmotility, gastritis, pancreatitis.
• Neurologic: Peripheral neuropathy, CNS involvement (rare).
• Hematologic: Lymphadenopathy, splenomegaly, cryoglobulinemia, lymphomas (increased risk).
• Dermatologic: Purpura, raynaud phenomenon.
• Constitutional: Fatigue, fever.

Diagnostic Criteria and Laboratory Findings:

Diagnosis typically requires demonstrating both glandular dysfunction and autoimmunity:

• Autoantibodies:

  • Anti-Ro (SSA): Present in ~50-70% of Sjögren's patients; associated with systemic manifestations.
  • Anti-La (SSB): Present in ~50-60% of Sjögren's patients; more specific for Sjögren's; almost always occurs with anti-Ro. Patients with anti-La almost always have anti-Ro as well.
  • Rheumatoid factor and ANA may also be positive.
• Schirmer Test: Tear production <5 mm in 5 minutes confirms keratoconjunctivitis sicca.
• Ocular Staining: Rose Bengal or lissamine green staining shows epithelial damage.
• Salivary Flow Testing: Unstimulated whole saliva <1.5 mL/15 minutes or stimulated parotid saliva <0.5 mL/minute confirms xerostomia.
• Minor Salivary Gland Biopsy: Shows lymphocytic infiltration, loss of acinar tissue, and possibly ectopic germinal centers. Gold standard for diagnosis but invasive; usually reserved if other features are equivocal.
• Imaging: Salivary gland ultrasound or scintigraphy shows reduced function and parenchymal changes.
• ESR, CRP: Usually elevated; nonspecific.
• CBC: Screen for cytopenias (lymphopenia, thrombocytopenia can occur).
• Comprehensive Metabolic Panel: Assess renal function and electrolytes.

Pharmacologic and Supportive Management:

There is no cure for Sjögren's, so management is primarily supportive (symptom relief) with some disease-modifying approaches:

1. For Dry Eyes:

• Artificial Tears: Preservative-free formulations; use frequently throughout the day (as often as needed, even hourly). Many brands available (Refresh, Systane, Hylo Gель).
• Punctal Plugs: Small silicone or collagen plugs inserted into the tear ducts to slow tear drainage; helps retain tears on the ocular surface. Reversible if side effects occur.
• Cyclosporine Ophthalmic Emulsion (Restasis): Immunosuppressant eye drops; reduces inflammation in lacrimal glands, increasing tear production. Applied twice daily; takes 4-6 weeks to show effect.
• Serum Tears: Autologous serum can be applied topically for severe dry eye; shows benefit but is expensive and requires preparation.
• Protective Eyewear: Wraparound sunglasses reduce sun exposure and wind irritation; moisture-chamber glasses trap moisture.
• Humidifiers: Especially at night; maintain ambient moisture.
• Avoid Triggers: Reduce time in air-conditioned environments, windy or smoky areas; blink consciously during screen time (computer vision syndrome).

2. For Dry Mouth:

• Frequent Sipping of Water: Teach patient to carry water bottle and sip throughout the day; helps with comfort and hydration.
• Sugar-Free Gum and Lozenges: Mechanical stimulation of salivary glands encourages saliva production. Patient should use multiple times daily. Sugar-free is essential to prevent caries.
• Saliva Substitutes: Artificial saliva products (e.g., Biotène, Mouth Kote) provide temporary lubrication; contain mucin, xylitol, or enzymes to mimic natural saliva.

• Salivary Stimulants:

  • Pilocarpine (Salagen): Cholinergic agonist that stimulates residual salivary gland function; dose 5 mg three times daily. Nursing considerations: Watch for cholinergic side effects (sweating, urinary frequency, muscle cramps, bradycardia). Not effective if glands are completely destroyed.
  • Cevimeline: Similar mechanism; alternative if pilocarpine not tolerated.

• Oral Care: Meticulous dental hygiene is critical.

  • Brush teeth 2-3 times daily with fluoride toothpaste.
  • Floss daily.
  • Use antimicrobial mouth rinse (chlorhexidine) to prevent caries and candidiasis.
  • Electric toothbrush may be easier for patients with joint involvement (arthritis).
  • Regular dental visits (every 3-6 months, more frequently than standard) for professional cleaning and fluoride application.
  • Consider high-strength fluoride gel applied nightly in custom trays to prevent caries.

3. Candidiasis (Oral Thrush) Prevention and Treatment:

• Prevention: Good oral hygiene, antimicrobial rinses, avoiding dry mouth as much as possible.
• Treatment: Antifungal rinses (nystatin), lozenges (clotrimazole), or systemic antifungal (fluconazole) if severe.

4. Disease-Modifying/Immunosuppressive Therapy:

• Limited evidence for systemic immunosuppression in Sjögren's; typically reserved for severe systemic manifestations (pulmonary, renal, neurologic involvement) or lymphoma risk.
• Hydroxychloroquine: Sometimes used as for other autoimmune diseases; may reduce systemic symptoms and joint pain.
• NSAIDs: For arthralgias.
• Immunosuppressants: Rituximab (anti-B cell monoclonal antibody) has shown promise in clinical trials for severe manifestations; occasionally used off-label. Other agents (mycophenolate, azathioprine) are used for systemic disease.

Nursing Diagnoses for Sjögren's Syndrome:

1. Dry Eye Syndrome (Keratoconjunctivitis Sicca) [Not NANDA but commonly documented]

   • Interventions: Artificial tears, protective eyewear, environmental modifications, cyclosporine eye drops, regular ophthalmology monitoring.

2. Dry Mouth Syndrome (Xerostomia) [Not NANDA but commonly documented]

   • Interventions: Water sipping, sugar-free gum/lozenges, saliva substitutes/stimulants, meticulous oral care, antimicrobial mouth rinse, dental checkups.

3. Risk for Impaired Oral Mucous Membrane r/t xerostomia and candidiasis risk

   • Interventions: Oral hygiene, antimicrobial rinses, antifungal agents as needed, dietary counseling (avoid dry foods, acidic drinks).

4. Chronic Pain r/t arthralgia/arthritis, oral discomfort

   • Interventions: NSAIDs, local analgesics, warm compresses, range-of-motion exercises.

5. Risk for Impaired Vision r/t keratoconjunctivitis sicca and corneal damage

   • Interventions: Artificial tears, protective eyewear, cyclosporine, regular ophthalmology evaluation, patient education.

6. Social Isolation r/t dry mouth affecting eating/social activities

   • Interventions: Supportive counseling, support groups, dietary accommodations, communication with social contacts.

Patient Education for Sjögren's Syndrome:

1. Dry Eye Management:

   • Use artificial tears frequently (every 1-2 hours or as often as needed).
   • Use preservative-free formulations to avoid irritation from preservatives.
   • Wear protective sunglasses, especially outdoors and in dry environments.
   • Use humidifier in bedroom at night.
   • Avoid smoke, wind, air conditioning when possible.
   • Take breaks during computer use; blink consciously.
   • Report vision changes, persistent eye pain, redness to ophthalmologist immediately.
   • Attend regular eye exams (every 6-12 months).

2. Dry Mouth Management:

   • Sip water throughout the day; carry water bottle.
   • Chew sugar-free gum or suck sugar-free lozenges multiple times daily to stimulate saliva.
   • Use saliva substitutes as needed for comfort.
   • Take pilocarpine or cevimeline if prescribed; understand it may take weeks to see benefit.
   • Avoid dry foods; eat moist, soft foods.
   • Avoid alcohol and caffeine (diuretic effect).
   • Avoid acidic drinks and foods (lemonade, citrus, vinegar) as they promote caries and irritate mucosa.

3. Oral and Dental Care — CRITICAL:

   • Brush teeth 2-3 times daily with fluoride toothpaste; use gentle technique to avoid gum trauma.
   • Floss daily to prevent caries and periodontal disease.
   • Use antimicrobial mouth rinse (chlorhexidine 0.12%) daily to prevent caries and candidiasis.
   • Attend dental checkups every 3-6 months (more frequently than general population due to high caries risk).
   • Use high-strength fluoride gel (1.1% sodium fluoride) nightly in custom trays if recommended by dentist.
   • Electric toothbrush may be easier if arthritis is present.
   • Report signs of candidiasis (white patches, oral discomfort) immediately.

4. Medication Adherence:

   • Take pilocarpine or cevimeline as prescribed; give it time to work (4-6 weeks).
   • Use cyclosporine eye drops as prescribed; it takes time to see benefit.
   • Consistent use of oral care products (fluoride toothpaste, antimicrobial rinse) is essential.

5. Nutrition and Dietary Modifications:

   • Eat moist foods (gravies, sauces, soups).
   • Avoid hard, dry, spicy foods that irritate mucosa.
   • Avoid very hot foods (can irritate).
   • Take small sips of water with meals to aid swallowing and provide lubrication.
   • Limit caffeine and alcohol (diuretic effects).
   • Consider nutritional supplements if weight loss occurs.

6. Support and Coping:

   • Join support groups (in-person or online) for Sjögren's patients; sharing experiences helps.
   • Understand that Sjögren's is a chronic condition; remission is unlikely, but symptoms can be well-managed.
   • Communicate with family and social contacts about your needs (need for water sips, dietary preferences).
   • Mental-health support if depression or anxiety develops (common due to chronic, bothersome symptoms).

Human Immunodeficiency Virus (HIV) infection represents the opposite end of the immune-dysfunction spectrum from autoimmunity. Rather than attacking itself, the immune system is progressively destroyed, leaving the person vulnerable to opportunistic infections and malignancies that do not typically occur in immunocompetent individuals. In the Philippines, HIV prevalence is rising, and the government has declared it one of the fastest-growing epidemics in the Asia-Pacific region. Understanding HIV pathophysiology, prevention, diagnosis, treatment, and the legal-ethical framework (RA 11166) is essential for all nurses.

Pathophysiology of HIV:

1. Retroviral Mechanism:
HIV is a retrovirus, meaning it carries its genetic material as RNA (not DNA like most organisms). The virus infects CD4+ T helper lymphocytes (also called CD4+ T cells or Th cells), which are the central coordinators of adaptive immune responses.

• Viral Entry: HIV attaches to CD4 receptors and CCR5 or CXCR4 co-receptors on the surface of T cells (and also macrophages and dendritic cells).
• Reverse Transcription: Once inside, HIV uses an enzyme called reverse transcriptase to convert its RNA genome into DNA (a step that DNA viruses don't need to do).
• Integration: The viral DNA is then integrated into the host cell's chromosome using another viral enzyme, integrase.
• Replication: The host cell machinery replicates the integrated viral DNA, producing new HIV particles that bud from the cell, destroying the T cell in the process.

2. Progressive CD4+ Decline:

• Normal CD4 Count: 500–1,600 cells/mm³ in healthy adults.
• CD4 Depletion: HIV progressively destroys CD4+ cells; the rate of decline varies (typically 50-100 cells/mm³ per year untreated, but highly variable). As CD4 count falls, cell-mediated immunity (Th1 and cytotoxic T cell responses) progressively weakens.

• Opportunistic Infections: As CD4 falls below certain thresholds, the person becomes vulnerable to infections that a normal immune system easily controls:

  • CD4 <500: Some fungal infections (candidiasis), TB.
  • CD4 <200: PCP (Pneumocystis jirovecii pneumonia)—the classic AIDS-defining infection; severe candidiasis; TB.
  • CD4 <100: CMV (cytomegalovirus), toxoplasmosis, MAC (Mycobacterium avium complex).
  • CD4 <50: CMV retinitis, severe cryptococcal meningitis.

3. Viral Load:

• Viral Load Definition: The number of HIV RNA copies per mL of blood; measures the amount of virus present.
• Significance: Higher viral load correlates with faster CD4 decline and greater infectivity (more likely to transmit to sexual partners or through blood exposure).
• Undetectable Viral Load: <50 copies/mL (or "undetectable"); indicates viral replication is suppressed. U=U (Undetectable = Untransmittable): Individuals with sustained undetectable viral load do not transmit HIV sexually, even without condom use (established by the PARTNER studies).

Natural History of HIV Infection — Three Stages:

Stage 1: Acute Retroviral Infection (Seroconversion Illness)

• Occurs 2-4 weeks after infection (range up to 10 weeks).
• Symptoms: Flu-like illness with fever (often high, >38.5°C), fatigue, myalgia, arthralgias, lymphadenopathy, rash (often truncal), headache, sore throat, diarrhea, nausea. Many patients are diagnosed late because these symptoms mimic flu or other common infections.
• Laboratory: During this window, viral load is extremely high (often >100,000 copies/mL) but antibodies are not yet present (negative HIV antibody test). The person is highly infectious.
• Prognosis: Self-limited; symptoms resolve over 1-2 weeks even without treatment. However, if treated during acute infection with antiretroviral therapy (ART), some studies suggest better long-term outcomes (lower viral setpoints, slower CD4 decline).

Stage 2: Clinical Latency (Asymptomatic Period)

• Duration: Highly variable, typically 8-10 years untreated, but ranges from <1 year (rapid progressor) to >15 years (long-term nonprogressor) depending on host factors (age, HLA type, genetic CCR5 variants) and viral factors (viral strain, replication rate).
• What's Happening: CD4 count is declining, viral replication continues (but at a controlled rate controlled only by immune response), but the person is clinically asymptomatic or has minimal symptoms (may have persistent lymphadenopathy).
• Infectivity: The person is still infectious; often transmits without realizing status because they feel well and may not know they are infected.
• Immune Collapse: During this time, the immune system is slowly being destroyed. Helper T cells are lost, undermining responses against other pathogens.

Stage 3: AIDS (Acquired Immunodeficiency Syndrome)

• Definition: AIDS is diagnosed when:

  1. CD4 count falls below 200 cells/mm³, OR
  2. An AIDS-defining opportunistic infection or malignancy occurs, regardless of CD4 count.
• Clinical Features: Constitutional symptoms (fever, weight loss, night sweats, diarrhea); opportunistic infections (PCP, TB, CMV, toxo, cryptococcal meningitis, candidiasis); opportunistic cancers (Kaposi sarcoma, non-Hodgkin lymphoma); CNS disease (AIDS dementia, HIV encephalopathy); wasting syndrome.
• Prognosis Without Treatment: Progressive decline; mean survival after AIDS diagnosis is ~1 year without treatment, but with modern ART, many patients live decades and may not progress to AIDS.

The Window Period — Critical for Testing and Counseling:

The window period is the interval between HIV infection and the point at which a test can reliably detect it. During this time, the person is infected and infectious but tests negative. This is a critical concept for nurses in counseling and testing:

• Antibody Tests (Traditional): Take 3-4 weeks on average to become positive; in rare cases, up to 6 months (very late seroconversion). Thus, negative antibody test does not rule out recent infection.
• Fourth-Generation Antigen/Antibody Tests: Detect both HIV antibodies and p24 antigen (a viral protein). These shorten the window to approximately 2-4 weeks from infection.
• Nucleic Acid (RNA) Tests (NAT/NAAT): Directly detect viral RNA; have the shortest window—about 1-2 weeks from infection. Not used for routine screening but for diagnosis in acute infection or monitoring.

Nursing Implications: Persons with negative test results but recent exposure should be counseled to retest at 6 weeks, and again at 3 months if exposure risk was very recent. During the window period, they must assume they are infected and take precautions (safer sex, no blood sharing) to prevent transmission. Repeat testing is also important because people often retest and believe they are negative when in fact they are in the window period.

Opportunistic Infections and AIDS-Defining Conditions — High-Yield for NLE:

As CD4 count falls, specific infections become more likely. Nursing must recognize these and anticipate diagnostic/therapeutic interventions:

1. Pneumocystis jirovecii Pneumonia (PCP) — The Classic AIDS-Defining Infection

• Epidemiology: Most common serious opportunistic infection in AIDS patients with CD4 <200.
• Symptoms: Gradual onset of dyspnea on exertion, nonproductive cough, fever, chest discomfort, fatigue. Often subacute (develops over weeks, unlike acute pneumonia).
• Examination: Tachypnea, tachycardia, possibly normal lung sounds (unlike bacterial pneumonia with crackles/consolidation).
• Diagnostics: CXR shows bilateral interstitial infiltrates (classic "ground-glass" appearance) but can be normal early in disease. Gold standard is induced sputum or bronchoalveolar lavage with Giemsa or immunofluorescent staining. LDH is often elevated; hypoxia on ABG or pulse oximetry.
• Treatment: Co-trimoxazole (TMP-SMX, Bactrim) is first-line for both treatment and prophylaxis. Dosing depends on severity. Corticosteroids (prednisone) are used if hypoxic to reduce inflammation.
• Prophylaxis: Co-trimoxazole prophylaxis is started when CD4 <200 and continued until CD4 >200 for ≥3 months on ART. Nursing instruction on PCP prophylaxis is essential.

2. Tuberculosis (TB) — Major Opportunistic Infection in the Philippines

• TB is the leading opportunistic infection and cause of death in people with HIV in the Philippines. This reflects both high TB prevalence in the community and the impact of immunosuppression.
• Presentation: Can range from latent TB infection (positive TST/IGRA, normal CXR, asymptomatic) to active TB disease. As CD4 falls, risk of progression from latent to active TB increases dramatically.
• Atypical Presentation: At very low CD4 (<50), TB may present with atypical findings (e.g., minimal pulmonary symptoms, extrapulmonary TB—lymphadenitis, disseminated disease).
• Co-infection Management: TB treatment is complex in HIV; drug interactions between TB medications and antiretrovirals are significant. Close TB-HIV coordination is essential. DOTS (Directly Observed Therapy, Short-course) is the recommended approach for TB in HIV.
• Immune Reconstitution Inflammatory Syndrome (IRIS): After starting ART, TB may paradoxically worsen initially as the immune system reconstitutes (TB-IRIS); this requires clinical judgment and sometimes temporarily holding ART.

3. Candidiasis (Fungal Infection)

• Oral Candidiasis (Thrush): Presents with white patches on tongue, palate, or pharynx; may be asymptomatic or cause burning mouth. Common when CD4 <200 but can occur at higher counts. Often the first sign of advanced immunosuppression.
• Esophageal Candidiasis: Extends to esophagus; causes dysphagia and odynophagia (pain on swallowing). Requires systemic antifungal therapy (fluconazole).
• Vulvovaginal Candidiasis: Frequent, recurrent vaginal yeast infections; common in women with CD4 <200.
• Treatment: Oral azoles (fluconazole) for oropharyngeal and esophageal disease; topical agents for oral thrush.

4. Cryptococcal Meningitis

• Epidemiology: Occurs at CD4 <100; common in many parts of world including Asia.
• Presentation: Subacute meningitis with headache, fever, stiff neck (but meningeal signs may be absent in severely immunocompromised patients—no robust inflammatory response). Altered mental status, cryptococcemia.
• Diagnosis: CSF culture; CSF cryptococcal antigen (CrAg) testing is highly sensitive and specific.
• Treatment: Amphotericin B (IV) for induction therapy, followed by fluconazole maintenance therapy. Often poor prognosis due to late diagnosis.

5. Cytomegalovirus (CMV)

• CMV Retinitis: Occurs at CD4 <50. Presents with floaters, visual field defects, vision loss. Direct visualization with dilated fundoscopy shows characteristic "pizza-pie" or hemorrhagic retinitis. Can lead to blindness if untreated. Requires IV ganciclovir or foscarnet (or intravitreal ganciclovir implants).
• CMV Esophagitis/Colitis: Less common but serious; causes dysphagia, abdominal pain, diarrhea.
• CMV Pneumonitis: Rare but serious; presents with cough, dyspnea, hypoxia.

6. Toxoplasmosis (CNS)

• Epidemiology: Occurs at CD4 <100; more common in seropositive patients (prior infection). Common in parts of world with high Toxoplasma prevalence.
• Presentation: Focal CNS lesions causing seizures, focal neurologic deficits, headache, altered mental status.
• Diagnosis: MRI or CT showing multiple ring-enhancing lesions; toxoplasma serology; sometimes brain biopsy.
• Treatment: Sulfadiazine plus pyrimethamine (or alternatives if allergic); prophylaxis with TMP-SMX when CD4 <100.

7. Mycobacterium avium Complex (MAC)

• Epidemiology: Occurs at CD4 <50; more common in severely advanced disease.
• Presentation: Fever, weight loss, diarrhea, lymphadenopathy, hepatosplenomegaly. Often disseminated.
• Diagnosis: Blood culture (more sensitive than biopsy); mycobacterial blood cultures.
• Treatment and Prophylaxis: Azithromycin or clarithromycin; prophylaxis started at CD4 <50.

8. AIDS Malignancies

• Kaposi Sarcoma: A vascular tumor caused by HHV-8 (human herpesvirus 8). Presents with purplish/reddish nodules on skin, mouth, or GI tract. More common in MSM (men who have sex with men). Often regresses with ART.
• Non-Hodgkin Lymphoma: B-cell lymphomas (including CNS lymphomas); increased risk at CD4 <100. Can present with constitutional symptoms, lymphadenopathy, or neurologic symptoms (if CNS).
• Invasive Cervical Cancer: Increased risk in HIV+ women; related to HPV co-infection. Requires aggressive screening and treatment.

9. HIV Wasting Syndrome

• Progressive weight loss (>10% of baseline), weakness, loss of appetite. Multifactorial (malabsorption, opportunistic infections, hypermetabolism). Can improve dramatically with ART; supplemental nutrition sometimes needed.

10. HIV Encephalopathy (AIDS Dementia Complex)

• Progressive CNS disease causing cognitive decline, behavioral changes, motor symptoms (tremor, ataxia, weakness). More common before ART era; now rare with effective treatment. Mechanism involves viral replication in macrophages and microglia in CNS.

Diagnosis of HIV:

Screening Tests (Initial):

• Fourth-Generation Antigen/Antibody Immunoassay: Detects both HIV antibodies and p24 antigen (a viral protein). More sensitive than previous-generation antibody-only tests; window period ~18-45 days.
• Rapid HIV Tests: Fingerstick or oral fluid tests; results in 15-30 minutes. Useful for quick screening but must be confirmed with additional testing before diagnosis.

Confirmation (Must Perform if Screening is Positive):

• Supplemental Antibody Test (e.g., HIV-1/HIV-2 Differentiation Immunoassay): Distinguishes between HIV-1 (most common) and HIV-2 (primarily West Africa).
• HIV RNA (Nucleic Acid) Test: Direct detection of viral RNA. Gold standard for diagnosis and most specific. Detects virus earlier than antibody tests (window period ~11-15 days). Also used for viral load monitoring.

Testing Algorithm (CDC/WHO Recommendation):

1. Fourth-generation antigen/antibody test → if negative: no HIV; if positive: proceed to step 2.
2. Supplemental antibody test (HIV-1/HIV-2 differentiation) → if positive: HIV-1 or HIV-2 (confirmed); if negative: proceed to step 3.
3. HIV-1 RNA (nucleic acid test) → if positive: acute HIV-1 infection (window period); if negative: inconclusive (retest in 1-2 weeks).

Baseline Evaluation After Diagnosis:

• CD4 Count: Establishes baseline immune status and guides opportunistic infection prophylaxis decisions.
• HIV Viral Load: Establishes baseline viral replication rate; used to assess need for urgent ART initiation and to monitor treatment response.
• Genotype (Drug Resistance Testing): Detects resistance to antiretroviral drugs; guides initial ART regimen selection.
• Other Labs: CBC (baseline cytopenias?), comprehensive metabolic panel (liver/kidney function), syphilis testing (RPR/VDRL), TB screening (tuberculin skin test or IGRA), hepatitis A/B/C serology, toxoplasma serology, CMV serology.
• History and Risk Factors: Sexual history, injection drug use, prior STIs, partner status, health insurance, adherence capacity, psychiatric history (affects ART choice).

Antiretroviral Therapy (ART) — Principles, Classes, and Nursing Considerations:

Fundamental Principles:

1. ART does not cure HIV but effectively suppresses viral replication. With modern regimens, most patients achieve undetectable viral load within weeks to months.
2. Combination therapy is essential: ART uses at least 3 drugs from 2 or more classes to target different steps in the viral life cycle. This prevents the emergence of drug-resistant HIV, which would cause treatment failure.
3. Adherence is critical: Missed doses allow viral replication, leading to drug resistance. Once resistance develops, that drug class may no longer work. Adherence counseling and support is a core nursing role.
4. Viral load monitoring: Regular viral load testing (typically every 3 months initially, then every 6-12 months if stable) documents suppression and guides treatment changes.
5. U=U: Undetectable = Untransmittable. Individuals with sustained undetectable viral load (<50 copies/mL) for at least 6 months do not transmit HIV through sexual contact, even without condom use. This has revolutionized HIV prevention and messaging.

Drug Classes (Mechanisms):

1. NRTIs (Nucleoside Reverse Transcriptase Inhibitors)

• Mechanism: Analog nucleosides that inhibit reverse transcriptase, the enzyme HIV uses to convert RNA to DNA.
• Examples: Tenofovir (TDF), lamivudine (3TC), emtricitabine (FTC), zidovudine (AZT), abacavir (ABC).

• Common Side Effects:

  • Zidovudine (AZT): Bone marrow suppression (anemia, leukopenia, thrombocytopenia); monitor CBC. Mitochondrial toxicity causing neuropathy, myopathy. Lactic acidosis (rare but serious).
  • Abacavir (ABC): Hypersensitivity reaction (fever, rash, GI/respiratory symptoms) in 5-8% (especially HLA-B*5701 positive); contraindicated if positive. Must screen before use.
  • Tenofovir (TDF): Renal toxicity and bone loss (osteoporosis); monitor renal function and bone density.
  • Lamivudine/Emtricitabine: Generally well-tolerated; minimal toxicity.
• Nursing Considerations: Monitor CBC (especially with AZT), renal function (especially TDF), screen for hypersensitivity (ABC). Educate about lactic acidosis symptoms (abdominal pain, nausea, rapid breathing).

2. NNRTIs (Non-Nucleoside Reverse Transcriptase Inhibitors)

• Mechanism: Bind directly to reverse transcriptase (different site than NRTIs), inhibiting its activity.
• Examples: Efavirenz (EFV), nevirapine (NVP), rilpivirine (RPV).

• Common Side Effects:

  • Efavirenz: CNS effects (dizziness, trouble concentrating, vivid dreams, nightmares, depression, suicidal ideation) in 50% of patients; take at bedtime. Rash, hepatotoxicity.
  • Nevirapine: Hepatotoxicity (can be severe, especially if CD4 >250 in women or >400 in men at start); rash (including Stevens-Johnson syndrome in rare cases); monitor LFTs closely.
  • Rilpivirine: Better tolerability than EFV/NVP; fewer CNS effects; rash, hepatotoxicity possible.
• Nursing Considerations: Counsel patients starting EFV about CNS effects and sleep; monitor mental health closely (screen for depression/suicidality). Monitor LFTs (especially NVP). Assess rash and distinguish from hypersensitivity.

3. Protease Inhibitors (PIs)

• Mechanism: Inhibit HIV protease, an enzyme the virus needs to process its proteins for assembly of new virions.
• Examples: Lopinavir/ritonavir (LPV/r), atazanavir (ATV), darunavir (DRV).
• Common Side Effects: GI upset (nausea, diarrhea, abdominal pain), lipodystrophy (abnormal fat redistribution), hyperglycemia, elevated triglycerides/cholesterol, hepatotoxicity.
• Drug Interactions: Ritonavir (used as a booster to increase PI levels) inhibits cytochrome P450; many drug interactions. Requires careful evaluation of concurrent medications.
• Nursing Considerations: Advise taking with food (improves absorption). Monitor for diarrhea; encourage hydration and fiber. Monitor lipids and glucose. Review all concurrent medications for interactions; educate patient that many OTC and prescription drugs may interact.

4. Integrase Strand Transfer Inhibitors (INSTIs)

• Mechanism: Inhibit integrase, the enzyme HIV uses to integrate its DNA into the host chromosome.
• Examples: Dolutegravir (DTG), raltegravir (RAL), bictegravir (BIC).
• Advantages: Generally well-tolerated; potent; rapid viral suppression; few drug interactions; not metabolized by P450.
• Common Side Effects: Generally minimal; insomnia, headache, rash possible but uncommon. Dolutegravir may increase glucose and weight gain slightly.
• Nursing Considerations: Among the easiest regimens to tolerate; good choice for patients with complex drug interactions or difficult-to-tolerate side effects. Favorable choice for many first-line regimens currently.

5. Entry/Fusion Inhibitors

• Mechanism: Block HIV from attaching to or fusing with CD4 cells.
• Examples: Enfuvirtide (T-20), maraviroc (MVC).
• Use: Second-line agents; reserved for treatment-experienced patients with resistant HIV. Enfuvirtide requires subcutaneous injection.
• Nursing Considerations: Rarely used in first-line; more common as salvage therapy in treatment-experienced patients.

First-Line ART Regimens (As of 2024, subject to updates):
Typical regimens include an INSTI backbone (e.g., DTG, RAL) plus two NRTIs, or alternative combinations. Specific recommendations vary by country, drug availability, and individual factors. The Philippine Department of Health (DOH) provides guidelines that are updated periodically.

When to Start ART:

• Current Recommendation: All HIV-infected persons, regardless of CD4 count, should be started on ART ("Treat All" strategy). Early treatment suppresses virus, reduces transmission risk (U=U), and prevents progression.
• Exceptions: In acute HIV infection, some experts defer therapy briefly if diagnosis is made during seroconversion illness, but most start immediately.
• Urgent (Same-Day/Within Days) Initiation: CD4 <50 (severe immunosuppression with high opportunistic infection risk), AIDS-defining illness present, pregnancy, TB co-infection, hepatitis co-infection.

Treatment Adherence — The Nursing Priority:

Non-adherence is the leading cause of treatment failure, drug resistance, and continued viral replication. Adherence >95% is needed to maintain viral suppression; even a few missed doses can compromise efficacy.

Strategies to Improve Adherence:

1. Patient Education: Clear explanation of HIV pathophysiology, how ART works, importance of adherence, expectations for viral load suppression, and U=U concept.
2. Simplified Regimens: Use fixed-dose combinations (multiple drugs in one tablet) and once-daily dosing when possible to reduce pill burden.
3. Addressing Barriers: Identify obstacles—side effects, complex regimens, depression/substance use, lack of transportation, food insecurity, unstable housing. Tailor interventions.
4. Pill Organizers/Reminders: Use medication organizers, cell phone alarms, or smart pill bottles.
5. Regular Monitoring: Frequent early visits; regular adherence checks; celebrate successes (undetectable VL).
6. Psychosocial Support: Mental-health screening/treatment; substance-use disorder treatment; support groups; family/partner involvement.
7. Directly Observed Therapy (DOT): In some settings, healthcare worker observes patient taking medication; ensures adherence.

Drug Interactions with ART:

ART drugs interact with many medications, especially those metabolized by cytochrome P450 enzymes. Critical for nursing: Always check interactions before adding new medications.

• PIs and NNRTIs: Significant interactions (enzyme inducers/inhibitors).
• INSTIs: Fewer interactions; generally safer with other drugs.
• Common Problem Drugs: Rifampicin (TB drug—reduces PI/NNRTI levels, but INSTIs are preferred if possible), antifungals (fluconazole increases PI levels), antibiotics, anticonvulsants (induce enzymes, reduce ART levels).

Immune Reconstitution Inflammatory Syndrome (IRIS):

IRIS occurs after starting ART, when CD4 count rises and immune function recovers. The paradoxical worsening of symptoms can occur:

• TB-IRIS: TB paradoxically worsens initially after ART; may see worsening chest symptoms, enlarged lymph nodes. Managed supportively; sometimes temporarily holding ART if severe.
• MAC-IRIS, CMV-IRIS, etc.: Other pathogens can also trigger IRIS.
• Risk Factors: Low baseline CD4 (<50), presence of opportunistic infection at ART start, rapid rise in CD4.
• Management: Continue ART if possible; manage inflammation with NSAIDs or corticosteroids; address underlying infection; close monitoring.

Special Populations:

1. Pregnancy and HIV:

• Prevention of Mother-to-Child Transmission (PMTCT): All pregnant women with HIV should be on ART achieving undetectable viral load to prevent transmission to baby.
• Medication: Most ART is safe in pregnancy. Some drugs to avoid (e.g., efavirenz in first trimester, though recent data less concerning; abacavir if HLA-B*5701 positive).
• Delivery: Vaginal delivery is safe if viral load <1,000 copies/mL. C-section reserved for higher VL.
• Infant Prophylaxis: Newborn given ART (usually AZT) for several weeks to prevent acquisition.
• Breastfeeding: In resource-rich settings like Philippines with safe water and formula availability, avoidance of breastfeeding is recommended. In resource-limited settings without safe water, continued ART by mother with undetectable VL allows breastfeeding.

2. TB-HIV Co-infection:

• Major challenge in Philippines; TB is leading OI death.
• Timing: TB treatment started first (usually); ART started within 2 weeks (some say up to 2 months for TB meningitis to avoid IRIS, but early ART is generally better).
• Drug Interactions: Rifampicin induces cytochrome P450; reduces PI and NNRTI levels. INSTIs (especially DTG) are preferred as they have better penetration despite enzyme induction. Or give higher-dose PIs.
• IRIS Risk: High risk if CD4 very low; TB symptoms may worsen initially with ART.

3. Hepatitis B and C Co-infection:

• Screen all HIV patients for HBsAg, anti-HBc, anti-HCV.
• If HBsAg+: Select ART regimen with activity against both (TDF or tenofovir alafenamide—TAF—plus 3TC or FTC provide dual coverage). Abrupt ART discontinuation risks HBV flare.
• If HCV+: Direct-acting antivirals (DAAs) can cure HCV even in HIV+ persons; improved outcomes especially if started after immune reconstitution (CD4 >200).

Post-Exposure Prophylaxis (PEP):

PEP is antiretroviral prophylaxis given to HIV-negative individuals after potential exposure to HIV (e.g., needlestick injury, sexual assault, unprotected sex with unknown status partner).

Timing: Must start within 72 hours of exposure (ideally as soon as possible—even hours are better than waiting). Efficacy decreases with time; starting after 72 hours is generally not recommended, though some guidelines allow up to 10 days in certain circumstances.

Duration: 28 days of ART (typically TruvadaTM, a fixed-dose combination of TDF+FTC, plus a third agent like RAL or DTG).

Efficacy: ~81-95% protective if taken consistently.
Nursing Role: Recognition of exposure (needlestick, sexual assault, unprotected intercourse with unknown/+ partner), urgent initiation of PEP evaluation (some hospitals have PEP protocols), education about adherence during 28-day course, and baseline/follow-up testing (at baseline, 6 weeks, 3 months, 6 months) to exclude acute infection and confirm seroconversion (if exposure truly occurred) or continued HIV-negative status.

Occupational PEP: Healthcare workers with needlestick or mucous membrane exposure should seek medical evaluation immediately; PEP started same day if indicated. Report and document incident; do not delay treatment waiting for source testing.

Pre-Exposure Prophylaxis (PrEP):

PrEP is antiretroviral medication given to HIV-negative, high-risk individuals to prevent acquisition.

Indication: Daily or event-driven PrEP for individuals at substantial risk:

• MSM (men who have sex with men) with multiple partners, receptive anal intercourse.
• Sex workers and clients of sex workers.
• Injection drug users sharing equipment.
• Partners of HIV+ individuals (serodiscordant couples); especially important if the positive partner is not yet on ART or has detectable VL.
• Transgender persons with risk behaviors.

Medication: Tenofovir/Emtricitabine (Truvada) daily PrEP is gold standard; 85-95% efficacy in preventing HIV infection when adherence is high. Newer regimens (e.g., cabotegravir LA, lenacapavir) are emerging.

Adherence: Requires daily dosing (or event-driven dosing in some protocols). Benefit decreases dramatically if not taken consistently.

Nursing Role: PrEP counseling for eligible individuals, baseline testing to confirm HIV-negative status, ensuring regular medical follow-up (every 3 months), renal function and bone health monitoring (especially TDF), STI screening (PrEP users often have high STI rates), contraception counseling (PrEP does not prevent pregnancy), adherence support, and education about sexual transmission risk reduction (PrEP is most effective with consistent condom use and STI testing).

Transmission and Prevention — Standard Precautions:

Routes of HIV Transmission:

1. Sexual Contact: Receptive anal intercourse (highest risk per act, ~1.4% per exposure), receptive vaginal intercourse (~0.08%), insertive anal intercourse (~0.04%), insertive vaginal intercourse (~0.04%), receptive oral sex (lower risk, ~0.04%), insertive oral sex (very low). Risk increased with STIs, genital inflammation, low CD4 count, high viral load, and lack of condom use.
2. Blood Exposure: Needle sharing (injection drug use), needlestick injury (~0.3% risk from hollow needle with blood), transfusion of contaminated blood, occupational exposure.
3. Perinatal (Mother-to-Child): During pregnancy, delivery, or breastfeeding. Prevented with maternal ART achieving undetectable VL, safe delivery, infant prophylaxis, and avoidance of breastfeeding (or continued maternal ART if breastfeeding is culturally mandated).
4. Other Body Fluids: Saliva (very low risk; thousands of exposures needed), tears (negligible risk), sweat (no risk), urine (no risk).

NOT Transmitted By:

• Casual contact (hugging, shaking hands, kissing on lips with intact mucosa—though risk increases with cuts/ulcers in mouth).
• Sharing utensils, toothbrushes, towels, clothing.
• Insect bites (mosquitoes, bed bugs).
• Toilet seats.
• Sharing air (no respiratory transmission).
• Spitting.

Standard (Universal) Precautions in Healthcare Settings:

Standard precautions apply to all patients, regardless of HIV status, and treat all blood and body fluids as potentially infectious. This is the cornerstone of infection control.

Hand Hygiene:

• Wash hands before and after every patient contact with soap and water.
• Use alcohol-based hand sanitizer if hands not visibly soiled.
• This is the single most important infection-control measure.

Gloves:

• Wear gloves for any contact with blood, body fluids, non-intact skin, or mucous membranes.
• Remove and dispose of gloves after patient care; do not touch other surfaces with soiled gloves.
• Wash hands after removing gloves (gloves can have micro-tears).

Gowns, Masks, Eye Protection:

• Wear gown if splashing of blood/body fluids is likely (e.g., blood draws, delivery).
• Wear mask and eye protection if splashing is possible (e.g., endotracheal suctioning, delivery, wound irrigation).
• N95 mask for TB (patient wears mask if suspected TB, or if coughing).

Sharps Safety — CRITICAL:

• Never recap needles. Recapping is the cause of most needlestick injuries.
• Place sharps (needles, lancets, scalpel blades) immediately in a rigid, puncture-proof container.
• Do not hand sharps to another person; place in designated container.
• Use safety-engineered devices (needles with guards, self-retracting syringes) when available.

Needlestick and Occupational Exposure Management:

If a healthcare worker sustains a needlestick or other percutaneous injury:

1. Immediate (Minutes After Injury):

   • Wash the puncture site with soap and water; do not try to squeeze out blood.
   • If mucous membrane exposure: flush with water or saline.
   • If skin exposure with visibly contaminated material: wash with soap and water.

2. Evaluation (Within Hours, Ideally Same Day):

   • Report to occupational health/employee health service or emergency department.
   • Document the incident: date, time, type of needle/injury, source patient (if known), exposure type (percutaneous, mucous membrane, skin).
   • Source patient testing: If source is known, test for HIV, Hepatitis B, Hepatitis C. (Some sources are tested with patient consent; others with implied consent depending on policy/law.)
   • Baseline testing of exposed worker: HIV, Hepatitis B, Hepatitis C (if source status unknown).

3. PEP Initiation (Within 72 Hours, Ideally Immediately):

   • If source is HIV-positive or status unknown and risk is deemed significant, start PEP immediately.
   • Typical PEP: 28-day course of 3-drug ART (often TDF+FTC+RAL or DTG).
   • Do not delay PEP waiting for source test results; start and adjust if source later tested negative.

4. Follow-Up:

   • Repeat HIV testing at 6 weeks, 3 months, and 6 months after exposure.
   • Repeat Hepatitis B and C testing if applicable (window periods vary).
   • Report side effects or adherence issues.
   • Provide counseling about safer practices and prevention of transmission during follow-up.

Specimen Handling and Disinfection:

• Handle all specimens as infectious; place in secondary containment if transport is needed.
• Clean spills with appropriate disinfectant (10% bleach solution, or EPA-approved disinfectant; allow 10-30 second contact time).
• Clean and disinfect all equipment used on HIV patients using standard hospital protocols.

Laundry:

• Standard hospital laundry procedures are adequate; no special handling needed for HIV patients.

Waste:

• Dispose of infectious waste (soiled dressings, sharps) in designated biohazard containers; incinerate or treat per institutional policy.

Legal and Ethical Framework in the Philippines:

Republic Act No. 11166 (Philippine HIV and AIDS Policy Act of 2018):

RA 11166 is the cornerstone of HIV policy in the Philippines and shapes nursing practice and responsibilities:

1. Confidentiality and Non-Disclosure:

• HIV status is strictly confidential; unauthorized disclosure is penalized by law.
• Healthcare providers, including nurses, must not disclose a patient's HIV status to family, employer, or others without explicit consent.
• Breach of confidentiality can result in civil and criminal penalties.
• Exception: Health care worker protection—occupational exposures must be documented and investigated, but the source patient's status should remain confidential.

2. Non-Discrimination:

• Discrimination against people living with HIV in employment, education, healthcare, housing, and travel is prohibited and punishable.
• Nurses must treat HIV patients with dignity and respect; refusal to care for HIV+ patients based on status is discrimination and unethical.
• Patients have the right to equal access to healthcare services.

3. Voluntary, Informed HIV Counseling and Testing (VCT):

• HIV testing must be voluntary, with informed consent.
• Pre-test counseling should provide information about HIV, testing methods, window period, meaning of results, and implications.
• Post-test counseling should explain results, provide support, and discuss next steps (prevention for negative, treatment for positive).
• Age of Consent: Minimum age for consent to VCT is 15 years (persons 15-17 can consent without parental permission in most cases, though some conditions apply). Younger persons may receive VCT with parental/guardian consent and in appropriate circumstances.

4. Healthcare Access and Services:

• Persons living with HIV have the right to access voluntary treatment, care, and support services provided by the government through DOH.
• ART is provided free by DOH to eligible patients.
• Opportunistic infection prophylaxis and treatment are part of comprehensive care.

5. Philippine National AIDS Council (PNAC) and DOH Programs:

• The government has established frameworks for prevention, testing, treatment, and support.
• DOH operates HIV treatment centers in major cities.
• Integration with TB programs is emphasized (TB-HIV co-management).

6. Prevention Programs:

• DOH promotes comprehensive HIV prevention: sexual health education, promotion of safe sex (condoms), PrEP, PEP, PMTCT, and harm reduction (needle/syringe programs for PWID).
• Emphasis on key populations (MSM, sex workers, transgender persons, PWID, migrant workers).

Nursing Roles and Responsibilities Under RA 11166:

1. Confidentiality: Strictly protect patient privacy; do not disclose HIV status without consent.
2. Non-Discrimination: Provide equitable, compassionate care; refuse to participate in discrimination.
3. Counseling and Testing: Perform HIV counseling and testing according to guidelines; explain window period and implications; address concerns.
4. Adherence Support: Counsel patients on medication adherence; identify and address barriers.
5. Infection Prevention: Adhere to standard precautions; prevent occupational transmission.
6. Education: Teach patients about HIV transmission, prevention, importance of partner notification, and safer practices.
7. Community Education: Participate in public-health messaging and STI/HIV awareness programs.
8. Referral: Ensure linkage to care, treatment, and psychosocial support services.
9. Advocacy: Support persons living with HIV; advocate for their rights and access to services; address stigma and discrimination.

Partner Notification and Disclosure:

While RA 11166 protects confidentiality of the HIV+ person, partners at risk have a right to know their status. Partner notification is complex:

• Ideally, the infected person discloses to partners and encourages testing.
• If the person refuses and public health is at risk, some countries allow "partner notification" by health authorities.
• In Philippines, current practice emphasizes counseling the patient about disclosure; partner notification by health authority is not routine practice but may be considered in special circumstances.
• Nursing Role: Counsel patients about importance of partner disclosure and testing; provide support for this difficult conversation; offer to help with partner referral/testing if patient consents.

Stigma and Discrimination:

Stigma toward people living with HIV is unfortunately common, even in healthcare settings, and undermines prevention, testing, and treatment efforts. Nurses have a responsibility to:

• Treat all patients with respect and dignity regardless of HIV status or risk group.
• Use language that is non-judgmental ("person living with HIV" not "AIDS patient" or "HIV sufferer"; "MSM" not "gay").
• Correct misinformation and educate colleagues about HIV transmission and prevention.
• Advocate for equitable treatment and access to care.
• Model professional, compassionate care that reduces stigma.